These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21073313)

  • 1. The Streptococcus pyogenes proteome: maps, virulence factors and vaccine candidates.
    Dmitriev AV; Chaussee MS
    Future Microbiol; 2010 Oct; 5(10):1539-51. PubMed ID: 21073313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability in the distribution of genes encoding virulence factors and putative extracellular proteins of Streptococcus pyogenes in India, a region with high streptococcal disease burden, and implication for development of a regional multisubunit vaccine.
    Sagar V; Bergmann R; Nerlich A; McMillan DJ; Nitsche Schmitz DP; Chhatwal GS
    Clin Vaccine Immunol; 2012 Nov; 19(11):1818-25. PubMed ID: 22971782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Distribution of emm genotypes and antibiotic susceptibility of Streptococcus pyogenes strains: analogy with the vaccine in development].
    Arslan U; Oryaşın E; Eskin Z; Türk Dağı H; Fındık D; Tuncer I; Bozdoğan B
    Mikrobiyol Bul; 2013 Apr; 47(2):318-23. PubMed ID: 23621731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streptococcal 5'-Nucleotidase A (S5nA), a Novel Streptococcus pyogenes Virulence Factor That Facilitates Immune Evasion.
    Zheng L; Khemlani A; Lorenz N; Loh JM; Langley RJ; Proft T
    J Biol Chem; 2015 Dec; 290(52):31126-37. PubMed ID: 26527680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular interactions of covR/S mutant group A Streptococci.
    Langshaw EL; Pandey M; Good MF
    Microbes Infect; 2018; 20(9-10):531-535. PubMed ID: 29287985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential compartmentalization of Streptococcus pyogenes virulence factors and host protein binding properties as a mechanism for host adaptation.
    Kilsgård O; Karlsson C; Malmström E; Malmström J
    Int J Med Microbiol; 2016 Nov; 306(7):504-516. PubMed ID: 27423808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete.
    Gillen CM; Courtney HS; Schulze K; Rohde M; Wilson MR; Timmer AM; Guzman CA; Nizet V; Chhatwal GS; Walker MJ
    J Biol Chem; 2008 Mar; 283(10):6359-66. PubMed ID: 18180300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
    Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
    J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with Streptococcus pyogenes nuclease A stimulates a high antibody response but no protective immunity in a mouse model of infection.
    Radcliff FJ; Fraser JD; Proft T
    Med Microbiol Immunol; 2015 Apr; 204(2):185-91. PubMed ID: 25119670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.
    van Sorge NM; Cole JN; Kuipers K; Henningham A; Aziz RK; Kasirer-Friede A; Lin L; Berends ETM; Davies MR; Dougan G; Zhang F; Dahesh S; Shaw L; Gin J; Cunningham M; Merriman JA; Hütter J; Lepenies B; Rooijakkers SHM; Malley R; Walker MJ; Shattil SJ; Schlievert PM; Choudhury B; Nizet V
    Cell Host Microbe; 2014 Jun; 15(6):729-740. PubMed ID: 24922575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knowing is half the battle: targeting virulence factors of group A Streptococcus for vaccine and therapeutics.
    Thomas CL; Lee SW
    Curr Drug Targets; 2012 Mar; 13(3):308-22. PubMed ID: 22206254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics.
    Davies MR; McIntyre L; Mutreja A; Lacey JA; Lees JA; Towers RJ; Duchêne S; Smeesters PR; Frost HR; Price DJ; Holden MTG; David S; Giffard PM; Worthing KA; Seale AC; Berkley JA; Harris SR; Rivera-Hernandez T; Berking O; Cork AJ; Torres RSLA; Lithgow T; Strugnell RA; Bergmann R; Nitsche-Schmitz P; Chhatwal GS; Bentley SD; Fraser JD; Moreland NJ; Carapetis JR; Steer AC; Parkhill J; Saul A; Williamson DA; Currie BJ; Tong SYC; Dougan G; Walker MJ
    Nat Genet; 2019 Jun; 51(6):1035-1043. PubMed ID: 31133745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Streptococcus agalactiae exoproteome.
    Papasergi S; Galbo R; Lanza-Cariccio V; Domina M; Signorino G; Biondo C; Pernice I; Poyart C; Trieu-Cuot P; Teti G; Beninati C
    J Proteomics; 2013 Aug; 89():154-64. PubMed ID: 23770297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
    Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quest for GAS vaccine.
    Pandey M; Good MF
    Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764
    [No Abstract]   [Full Text] [Related]  

  • 16. Status of research and development of vaccines for Streptococcus pyogenes.
    Steer AC; Carapetis JR; Dale JB; Fraser JD; Good MF; Guilherme L; Moreland NJ; Mulholland EK; Schodel F; Smeesters PR
    Vaccine; 2016 Jun; 34(26):2953-2958. PubMed ID: 27032515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
    Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
    mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.
    Fritzer A; Senn BM; Minh DB; Hanner M; Gelbmann D; Noiges B; Henics T; Schulze K; Guzman CA; Goodacre J; von Gabain A; Nagy E; Meinke AL
    Infect Immun; 2010 Sep; 78(9):4051-67. PubMed ID: 20624906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an anti-streptococcal vaccine.
    García PC; Paillavil BA; Scioscia N; Dale JB; Legarraga P; Salazar-Echegarai FJ; Bueno SM; Kalergis AM; Wozniak A
    Microbiol Immunol; 2018 Nov; 62(11):711-719. PubMed ID: 30357922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and structural properties of a novel protein and virulence factor (Protein sHIP) in Streptococcus pyogenes.
    Wisniewska M; Happonen L; Kahn F; Varjosalo M; Malmström L; Rosenberger G; Karlsson C; Cazzamali G; Pozdnyakova I; Frick IM; Björck L; Streicher W; Malmström J; Wikström M
    J Biol Chem; 2014 Jun; 289(26):18175-88. PubMed ID: 24825900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.